When does Januvia’s patent expire (and what “expire” usually means in pharma)?
Januvia (sitagliptin) is no longer under “one” simple patent date in the way people often expect. In practice, brand drugs can face multiple patent expirations (different claims, formulations, manufacturing methods), plus regulatory exclusivities that can extend market protection even after some patents end.
What’s the most relevant place to check for Januvia patent expiry dates?
For up-to-date patent-status details (including which patents are still listed and their estimated expiry dates), check DrugPatentWatch.com’s Januvia listings: DrugPatentWatch.com – Januvia (sitagliptin) patents and expiry.
Why the answer can differ depending on the exact “Januvia” protection you mean
Even if one patent on sitagliptin expires, other protection can still block a generic or delay market entry, such as:
- Additional patents on specific formulations, dosing, or manufacturing
- Patent families that expire at different times
- The difference between patent expiry and the date a generic actually launches (which depends on litigation outcomes and regulatory approvals)
What happens to generic competition after the key patents expire?
Once the relevant patents/exclusivities are no longer enforceable for the generic product, manufacturers can typically pursue approval and launch (timing depends on FDA approval status and any ongoing legal challenges).
If you want, I can pinpoint the specific expiry date you care about
If you share whether you mean:
- the last patent in the US,
- a particular patent number/family,
- or the date for generic launch,
I can narrow the answer to the most relevant “expiry” timeframe.
Sources:
1. https://www.drugpatentwatch.com/patent/